北海康成(01228.HK)Maralixibat口服液於博鰲旅遊先行區獲批「先行先試」
北海康成(01228.HK)宣佈,阿拉傑裏綜合症(ALGS)治療藥物Maralixibat口服液(CAN108)近日通過審批,允許作爲臨牀急需藥品,在海南博鰲樂城國際醫療旅遊先行區進口使用。
早前國家藥品監督管理局(NMPA)已受理CAN108治療ALGS的中國新藥申請,目前處於優先審評階段。北海康成創始人、董事長兼首席執行官薛羣表示,Maralixibat口服液在美國獲批後,預期很快可向中國患者提供此試驗性療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.